Sevening Capital

elsewhere's corpus doesn't profile Sevening Capital directly — the only material is two deal mentions in FreeS Capital's funding roundups. What they establish: Sevening Capital (七晟资本/七晟基金) is described in a 2023 FreeS piece as Septwolves' (七匹狼) investment fund, when it co-led with 硅港资本 a tens-of-millions-yuan Pre-A+ round into carbon-fiber composites maker Huayu New Materials . It surfaced again in a January 2025 roundup as a co-investor — alongside Tailong/Taikun Capital (lead) and Tianhui Capital — in a new round for Shize Biotech, where FreeS Capital, Qiming, Lilly Asia Ventures and Sequoia China doubled down as existing shareholders . Beyond those two life-sciences/advanced-materials appearances, elsewhere has no coverage of the fund's size, strategy, or team.